{"title":"针对COVID-19的靶向部位特异性治疗","authors":"P. Iversen, T. Porter, N. Kipshidze, N. Kipshidze","doi":"10.35248/2157-7439.20.11.548","DOIUrl":null,"url":null,"abstract":"No definitive therapies for COVID-19 have yet to be identified. The several hundred planned or ongoing clinical trials globally will provide some insights into therapies that may or may not work. The overwhelming majority of therapeutics relies on the systemic delivery of drugs; however, COVID-19 is largely localized to the lungs with some subgroups afflicted in other organ systems. We propose the use of a targeted drug delivery approach in which therapeutics can be delivered using engineered delivery vehicles to reach damaged lung tissue directly.","PeriodicalId":16532,"journal":{"name":"Journal of Nanomedicine & Nanotechnology","volume":"33 5","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeted Site-Specific Therapeutics for COVID-19\",\"authors\":\"P. Iversen, T. Porter, N. Kipshidze, N. Kipshidze\",\"doi\":\"10.35248/2157-7439.20.11.548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"No definitive therapies for COVID-19 have yet to be identified. The several hundred planned or ongoing clinical trials globally will provide some insights into therapies that may or may not work. The overwhelming majority of therapeutics relies on the systemic delivery of drugs; however, COVID-19 is largely localized to the lungs with some subgroups afflicted in other organ systems. We propose the use of a targeted drug delivery approach in which therapeutics can be delivered using engineered delivery vehicles to reach damaged lung tissue directly.\",\"PeriodicalId\":16532,\"journal\":{\"name\":\"Journal of Nanomedicine & Nanotechnology\",\"volume\":\"33 5\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nanomedicine & Nanotechnology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2157-7439.20.11.548\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanomedicine & Nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2157-7439.20.11.548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
No definitive therapies for COVID-19 have yet to be identified. The several hundred planned or ongoing clinical trials globally will provide some insights into therapies that may or may not work. The overwhelming majority of therapeutics relies on the systemic delivery of drugs; however, COVID-19 is largely localized to the lungs with some subgroups afflicted in other organ systems. We propose the use of a targeted drug delivery approach in which therapeutics can be delivered using engineered delivery vehicles to reach damaged lung tissue directly.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
